Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab
Georges
G
Abu-Alfa
Ali
A
D000328:Adult; D002140:California / Q000453:epidemiology; D015984:Causality; D015897:Comorbidity; D005260:Female; D005355:Fibrosis; D019786:Gadolinium DTPA; D006801:Humans; D015994:Incidence; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000453:epidemiology* / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012871:Skin Diseases / Q000175:diagnosis / Q000453:epidemiology*
C064925:gadodiamide; D019786:Gadolinium DTPA